<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412071</url>
  </required_header>
  <id_info>
    <org_study_id>Penile microbiome antibiotics</org_study_id>
    <nct_id>NCT03412071</nct_id>
  </id_info>
  <brief_title>Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men</brief_title>
  <official_title>Testing the Ability of a Microbiome - Focused Intervention to Reduce HIV Susceptibility in Ugandan Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UVRI-IAVI HIV Vaccine Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Entebbe General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will assess the impact of four antimicrobial products (3 topical, one
      systemic) on the foreskin microbiome and HIV susceptibility of foreskin-derived CD4+ T cells.
      Participants will include HIV-uninfected Ugandan men presenting for elective male
      circumcision to reduce their HIV risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE: The foreskin is the site of most HIV acquisition in uncircumcised heterosexual
      men, and male circumcision (MC) reduces HIV risk by almost 60%. However, cultural and
      practical barriers have led to suboptimal uptake. Foreskin inflammation, defined by elevated
      levels of pro-inflammatory cytokines in the prepuce, is a key determinant of HIV acquisition
      risk in uncircumcised men, and anaerobic bacteria within the foreskin microbiome may be an
      important cause of this inflammation.

      OBJECTIVES: A pilot in vivo - in vitro clinical study of four potential interventions to
      reduce HIV susceptibility in the foreskin by altering the microbiome. The study is a
      collaboration between the University of Toronto, IAVI-UVRI, and the Entebbe General Hospital.
      We will recruit 125 men presenting for elective MC, along with regular female sexual partners
      (if applicable). Participants will be randomized (n=25 per group) to immediate MC, or to one
      of four intervention arms: twice-daily application of topical metronidazole 0.75%;
      twice-daily application of topical clindamycin 2%; twice daily application of hydrogen
      peroxide 1%; or oral tinidazole 2g once a day for two days. Swabs for immune and microbiome
      studies will be collected before and after product. After 4 weeks the MC procedure will be
      performed; foreskin CD4+ T cell susceptibility to HIV will be quantified using a flow
      cytometry-based pseudovirus assay, and tissue immunohistochemistry performed. The primary and
      secondary endpoints are outlined below. A secondary study will assess the impact of penile
      topical antibiotic application on immunology and the microbiome in the genital tract of
      female sexual partners.

      OUTCOMES: This in vivo - in vitro clinical trial will define the causal role of the penile
      microbiome in HIV susceptibility, and will assess potential strategies to take forward into
      HIV efficacy trials in uncircumcised heterosexual men.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">December 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open label with 5 arms</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% HIV entry into foreskin derived CD4+ T cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>This measure will utilize a validated pseudovirus entry assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue density of HIV-susceptible CD4+ T cells</measure>
    <time_frame>4 weeks</time_frame>
    <description>The density of CD4+ T cells in foreskin tissues will be assayed using immunohistochemistry, and the % pseudovirus entry (see primary endpoint, above) will be used to calculate the tissue density of HIV-susceptible CD4+ T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T cell subsets in foreskin tissue</measure>
    <time_frame>4 weeks</time_frame>
    <description>Immunofluorescence microscopy (IF) will be used to quantify CD4+ T cell subsets foreskin tissue after circumcision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of Langerhans cells in foreskin tissue</measure>
    <time_frame>4 weeks</time_frame>
    <description>Immunofluorescence microscopy (IF) will be used to quantify Langerhans cells in foreskin tissue after circumcision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of foreskin inflammation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Cytokine/chemokines will be assayed by ELISA, and foreskin inflammation defined as the presence of â‰¥3/7 inflammatory cytokines within the top quartile for that cytokine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foreskin microbiome composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>The foreskin (prepuce) microbiome will be characterized based on 16S rRNA sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foreskin tissue explant HIV susceptibility</measure>
    <time_frame>4 weeks</time_frame>
    <description>Foreskin tissue susecptibility to HIV infection will be quantified, based on p24 ELISA after ex vivo incubation with a primary HIV isolate.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Foreskin HIV Susceptibility</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral tinidazole group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical metronidazole (0.75%) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical clindamycin (2%) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical hydrogen peroxide (1%) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Tinidazole</intervention_name>
    <description>Please see description under arms</description>
    <arm_group_label>Oral tinidazole group</arm_group_label>
    <other_name>FASIGYN 500mgs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical metronidazole</intervention_name>
    <description>Please see description under arms</description>
    <arm_group_label>Topical metronidazole (0.75%) group</arm_group_label>
    <other_name>Rozex 0.75%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Clindamycin</intervention_name>
    <description>Please see description under arms</description>
    <arm_group_label>Topical clindamycin (2%) group</arm_group_label>
    <other_name>Dalacin cream 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Hydrogen Peroxide</intervention_name>
    <description>Please see description under arms</description>
    <arm_group_label>Topical hydrogen peroxide (1%) group</arm_group_label>
    <other_name>Crystacide 1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Enrollment criteria include:

          1. Aged 18 years or older

          2. Biological male

          3. Uncircumcised

          4. HIV seronegative

          5. Willing to comply with the requirements of the protocol

          6. No current sexually transmitted infection (N. gonorrhoeae or C. trachomatis)

          7. No clinically relevant genital symptoms / signs
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Foreskin HIV susceptibility can only be assessed in biological males.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Kaul, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald M Galiwango, MBChB/MSc</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupert Kaul, MD/PhD</last_name>
    <phone>(416) 946-7054</phone>
    <email>rupert.kaul@utoronto.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>UVRI-IAVI HIV Vaccine Program</name>
      <address>
        <city>Entebbe</city>
        <state>Wakiso</state>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard S Bagaya, PhD</last_name>
      <phone>+256787082820</phone>
      <email>bbagaya@iavi.or.ug</email>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Gray RH, Wawer MJ, Kigozi G. Programme science research on medical male circumcision scale-up in sub-Saharan Africa. Sex Transm Infect. 2013 Aug;89(5):345-9. doi: 10.1136/sextrans-2012-050595. Epub 2013 May 22.</citation>
    <PMID>23698513</PMID>
  </reference>
  <reference>
    <citation>Liu CM, Hungate BA, Tobian AA, Serwadda D, Ravel J, Lester R, Kigozi G, Aziz M, Galiwango RM, Nalugoda F, Contente-Cuomo TL, Wawer MJ, Keim P, Gray RH, Price LB. Male circumcision significantly reduces prevalence and load of genital anaerobic bacteria. MBio. 2013 Apr 16;4(2):e00076. doi: 10.1128/mBio.00076-13.</citation>
    <PMID>23592260</PMID>
  </reference>
  <reference>
    <citation>Prodger JL, Gray R, Kigozi G, Nalugoda F, Galiwango R, Hirbod T, Wawer M, Hofer SO, Sewankambo N, Serwadda D, Kaul R. Foreskin T-cell subsets differ substantially from blood with respect to HIV co-receptor expression, inflammatory profile, and memory status. Mucosal Immunol. 2012 Mar;5(2):121-8. doi: 10.1038/mi.2011.56. Epub 2011 Nov 16.</citation>
    <PMID>22089029</PMID>
  </reference>
  <reference>
    <citation>Prodger JL, Gray RH, Shannon B, Shahabi K, Kong X, Grabowski K, Kigozi G, Nalugoda F, Serwadda D, Wawer MJ, Reynolds SJ, Liu CM, Tobian AA, Kaul R. Chemokine Levels in the Penile Coronal Sulcus Correlate with HIV-1 Acquisition and Are Reduced by Male Circumcision in Rakai, Uganda. PLoS Pathog. 2016 Nov 29;12(11):e1006025. doi: 10.1371/journal.ppat.1006025. eCollection 2016 Nov.</citation>
    <PMID>27898732</PMID>
  </reference>
  <reference>
    <citation>Prodger JL, Hirbod T, Kigozi G, Nalugoda F, Reynolds SJ, Galiwango R, Shahabi K, Serwadda D, Wawer MJ, Gray RH, Kaul R; Rakai Genital Immunology Research Group. Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda. Mucosal Immunol. 2014 May;7(3):634-44. doi: 10.1038/mi.2013.83. Epub 2013 Oct 23.</citation>
    <PMID>24150258</PMID>
  </reference>
  <reference>
    <citation>Menard JP. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int J Womens Health. 2011;3:295-305. doi: 10.2147/IJWH.S23814. Epub 2011 Aug 23.</citation>
    <PMID>21976983</PMID>
  </reference>
  <reference>
    <citation>Rashed HT. Evaluation of the effect of hydrogen peroxide as a mouthwash in comparison with chlorhexidine in chronic periodontitis patients: A clinical study. J Int Soc Prev Community Dent. 2016 May-Jun;6(3):206-12. doi: 10.4103/2231-0762.183114. Epub 2016 May 30.</citation>
    <PMID>27382535</PMID>
  </reference>
  <reference>
    <citation>Armstrong NR, Wilson JD. Tinidazole in the treatment of bacterial vaginosis. Int J Womens Health. 2010 Aug 9;1:59-65.</citation>
    <PMID>21072275</PMID>
  </reference>
  <reference>
    <citation>Baggaley R, Doherty M, Ball A, Ford N, Hirnschall G. The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S159-60. doi: 10.1093/cid/civ091.</citation>
    <PMID>25972496</PMID>
  </reference>
  <reference>
    <citation>TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016 May;16(5):565-575. doi: 10.1016/S1473-3099(15)00536-8. Epub 2016 Jan 29. Erratum in: Lancet Infect Dis. 2016 Jun;16(6):636.</citation>
    <PMID>26831472</PMID>
  </reference>
  <reference>
    <citation>Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005 Nov;2(11):e298. Epub 2005 Oct 25. Erratum in: PLoS Med. 2006 May;3(5):e298.</citation>
    <PMID>16231970</PMID>
  </reference>
  <reference>
    <citation>Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007 Feb 24;369(9562):643-56.</citation>
    <PMID>17321310</PMID>
  </reference>
  <reference>
    <citation>Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangen F, Bacon MC, Williams CF, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007 Feb 24;369(9562):657-66.</citation>
    <PMID>17321311</PMID>
  </reference>
  <reference>
    <citation>Sgaier SK, Reed JB, Thomas A, Njeuhmeli E. Achieving the HIV prevention impact of voluntary medical male circumcision: lessons and challenges for managing programs. PLoS Med. 2014 May 6;11(5):e1001641. doi: 10.1371/journal.pmed.1001641. eCollection 2014 May.</citation>
    <PMID>24800840</PMID>
  </reference>
  <reference>
    <citation>Kigozi G, Wawer M, Ssettuba A, Kagaayi J, Nalugoda F, Watya S, Mangen FW, Kiwanuka N, Bacon MC, Lutalo T, Serwadda D, Gray RH. Foreskin surface area and HIV acquisition in Rakai, Uganda (size matters). AIDS. 2009 Oct 23;23(16):2209-13. doi: 10.1097/QAD.0b013e328330eda8.</citation>
    <PMID>19770623</PMID>
  </reference>
  <reference>
    <citation>Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW, Ndung'u T, Dong KL, Walker BD, Fichorova RN, Kwon DS. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity. 2015 May 19;42(5):965-76. doi: 10.1016/j.immuni.2015.04.019.</citation>
    <PMID>25992865</PMID>
  </reference>
  <reference>
    <citation>Bolduc JF, Ouellet M, Hany L, Tremblay MJ. Toll-Like Receptor 2 Ligation Enhances HIV-1 Replication in Activated CCR6+ CD4+ T Cells by Increasing Virus Entry and Establishing a More Permissive Environment to Infection. J Virol. 2017 Jan 31;91(4). pii: e01402-16. doi: 10.1128/JVI.01402-16. Print 2017 Feb 15.</citation>
    <PMID>27928019</PMID>
  </reference>
  <reference>
    <citation>Esra RT, Olivier AJ, Passmore JA, Jaspan HB, Harryparsad R, Gray CM. Does HIV Exploit the Inflammatory Milieu of the Male Genital Tract for Successful Infection? Front Immunol. 2016 Jun 24;7:245. doi: 10.3389/fimmu.2016.00245. eCollection 2016. Review.</citation>
    <PMID>27446076</PMID>
  </reference>
  <reference>
    <citation>Bukusi E, Thomas KK, Nguti R, Cohen CR, Weiss N, Coombs RW, Holmes KK. Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sex Transm Dis. 2011 Jun;38(6):483-9.</citation>
    <PMID>22256334</PMID>
  </reference>
  <reference>
    <citation>Jhingta P, Bhardwaj A, Sharma D, Kumar N, Bhardwaj VK, Vaid S. Effect of hydrogen peroxide mouthwash as an adjunct to chlorhexidine on stains and plaque. J Indian Soc Periodontol. 2013 Jul;17(4):449-53. doi: 10.4103/0972-124X.118315.</citation>
    <PMID>24174723</PMID>
  </reference>
  <reference>
    <citation>V Sgibnev A, A Kremleva E. Vaginal Protection by H2O2-Producing Lactobacilli. Jundishapur J Microbiol. 2015 Oct 17;8(10):e22913. doi: 10.5812/jjm.22913. eCollection 2015 Oct.</citation>
    <PMID>26587206</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Rupert Kaul</investigator_full_name>
    <investigator_title>Professor - Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Hydrogen Peroxide</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

